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Hypoxic tumor-associated macrophages (TAMs) ac-
quire angiogenic and immunosuppressive proper-
ties. Yet it remains unknown if metabolic changes
influence these functions. Here, we argue that
hypoxic TAMs strongly upregulate the expression
of REDD1, a negative regulator of mTOR. REDD1-
mediated mTOR inhibition hinders glycolysis in
TAMs and curtails their excessive angiogenic
response, with consequent formation of abnormal
blood vessels. Accordingly, REDD1 deficiency in
TAMs leads to the formation of smoothly aligned,
pericyte-covered, functional vessels, which prevents
vessel leakiness, hypoxia, and metastases. Mecha-
nistically, highly glycolytic REDD1-deficient TAMs
outcompete endothelial cells for glucose usage that
thwarts vascular hyperactivation and promotes the
formation of quiescent vascular junctions. Tuning
down glycolysis in REDD1 knockout TAMs re-estab-
lishes abnormal angiogenesis and metastases. On
this basis, we prove that the anti-tumor effect of
mTOR inhibitors is partly countered by the delete-
rious outcome of these drugs on TAMs. Our data pro-
vide a functional link between TAM metabolism and
tumor angiogenesis.
INTRODUCTION
Heterogeneity of macrophages has been long recognized as
the result of the plasticity and versatility of these cells to different
microenvironmental stimuli. In tumors, macrophages are in-
volved in blood and lymphatic vessel formation, cancer cell inva-
sion and distal dissemination, as well as immune suppression
(Mantovani and Allavena, 2015). Recently, we have proved that
tumor-associated macrophages (TAMs) within hypoxic niches
of the tumor acquire a pro-angiogenic, pro-invasive, and tolero-
genic phenotype (Casazza et al., 2013).CHypoxic TAMs display strong alterations in the expression of
several metabolic genes as they are forced to adapt their
metabolism to low oxygen tension in order to meet their energy
requirements (Laoui et al., 2014). Besides oxygen availability,
cytokines also have an impact on macrophage metabolism,
and different activation stimuli can drive opposing metabolic
changes. For example, in vitro classically activated, pro-inflam-
matory M1 macrophages switch their metabolism toward
enhanced anaerobic glycolysis, pentose phosphate pathway
activation, and protein and fatty acid synthesis (Tannahill
et al., 2013). On the other hand, alternative activation of
macrophages by M2-inducing stimuli such as IL-4, IL-10, and
IL-13 leads to a phenotype that more closely resembles the fea-
tures of protumoral TAMs and is associated with enhanced
oxidative phosphorylation, with no changes in glycolysis (Vats
et al., 2006). Intriguingly, the metabolic characteristics of mac-
rophages in the context of cancer have never been investi-
gated, so it remains unknown if a change in TAM metabolism
could influence their phenotype and thus affect cancer growth
and metastasis.
The mechanistic target of rapamycin (mTOR) is a key nutrient
and energy sensor that, on the basis of nutrient availability, reg-
ulates downstream metabolic processes such as glycolysis, de
novo lipogenesis, protein synthesis, and transcription (Laplante
and Sabatini, 2012). Hypoxia blocks mTOR function through
HIF-mediated transcriptional induction of the mTOR complex
1 (mTORC1) inhibitor REDD1 (regulated in development and
DNA damage response 1; otherwise known as RTP801 or
DDIT4) (Brugarolas et al., 2004). Other than hypoxia, REDD1
is also induced by a variety of other stress conditions which
are major features in cancer, including endoplasmic reticular
stress (Wang et al., 2003), oxidative stress (Lin et al., 2005), os-
motic stress (Wang et al., 2003), DNA-damaging agents (Ellisen
et al., 2002), and cytokine stimulation such as IL-6 (Song et al.,
2011).
Recent studies have shown that constitutive mTOR activation
renders macrophages refractory to IL-4-induced M2 polariza-
tion, but increases inflammatory responses upon M1 stimuli (By-
les et al., 2013). On the basis of the knowledge that hypoxia and
stress conditions specifically control mTOR activity through
REDD1 regulation, we hypothesized that the REDD1/mTORell Metabolism 24, 1–15, November 8, 2016 ª 2016 Elsevier Inc. 1
(legend on next page)
2 Cell Metabolism 24, 1–15, November 8, 2016
Please cite this article in press as: Wenes et al., Macrophage Metabolism Controls Tumor Blood Vessel Morphogenesis and Metastasis, Cell Meta-
bolism (2016), http://dx.doi.org/10.1016/j.cmet.2016.09.008
Please cite this article in press as: Wenes et al., Macrophage Metabolism Controls Tumor Blood Vessel Morphogenesis and Metastasis, Cell Meta-
bolism (2016), http://dx.doi.org/10.1016/j.cmet.2016.09.008axis is a central homeostatic relay that links macrophage meta-
bolism to the immunosuppressive and/or pro-angiogenic prop-
erties of hypoxic TAMs. Here, we studied the role of REDD1/
mTOR in the control of macrophage and TAM metabolism in
hypoxia and how this induces phenotypic changes that influence
cancer progression.
RESULTS
REDD1 Is Upregulated in Hypoxic TAMs
A large body of evidence in several tumor types has proved that
the induction of the hypoxia-responsive glucose transporter
GLUT1 strongly and unequivocally correlates with oxygen
shortage (Airley et al., 2003; Rademakers et al., 2011; Sennino
et al., 2012). By looking at the pattern of GLUT1 and the hypox-
ia-probe pimonidazole in subcutaneous Lewis lung carcinomas
(LLC), orthotopic E0771 breast cancer, and spontaneous PyMT
mammary tumors, we confirmed that these two markers
strongly overlapped and GLUT1+ TAMs were always positive
for pimonidazole (Figures 1A and 1B). Thus, we sorted GLU-
T1high (hypoxic) macrophages and GLUT1low/ (normoxic) mac-
rophages from LLC, E0771, and PyMT tumors and healthy
tissues (i.e., bone marrow [BM] or lung). Strikingly, the mRNA
levels of Redd1 were significantly higher in GLUT1high versus
GLUT1low/ tissue macrophages, while TAMs showed overall
greater levels of Redd1, which was the highest in GLUT1high
TAMs (Figure 1C). In line, REDD1 staining in TAMs residing in-
side the hypoxic areas was much higher than in TAMs from
the normoxic niches (Figure 1D). To dissect the contribution
of hypoxia versus tumor-specific stimuli, we built an in vitro sys-
tem in which BM-derived macrophages (BMDMs) were stimu-
lated with LLC tumor-conditioned medium (TCM) as previously
shown (Colegio et al., 2014; Finisguerra et al., 2015) and thus
generated TAM-like macrophages (TAMs-L) that were exposed
to normoxia or hypoxia. In this setting, several typical TAM
markers followed a similar expression profile as LLC tumor-
sorted TAMs (Figures S1A–S1J, available online). As in vivo,
Redd1 transcript and protein levels were both synergically
increased when TAMs-L were cultured in hypoxia (Figures 1G
and 1H). Overall, REDD1 is induced in TAMs (compared
with normal macrophages) and gets strongly upregulated in
hypoxia.Figure 1. REDD1 Upregulation in Hypoxic TAMs Suppresses mTOR Ac
(A) Representative images of GLUT1, pimonidazole (PIMO), and F4/80 staining (T
(B) Histological analysis indicating the percentage of F4/80+ TAMs that are either G
and hypoxic (PIMO+) areas of LLC, E0771, or PyMT tumors. Total mice ten per t
(C) Redd1 expression in CD11b+ F4/80+ macrophages sorted from normoxic (GL
mice or tumors. Pooled data from two independent experiments, total mice four
(D) Histological analysis of the percentage of REDD1 and F4/80-double positive
(E and F) Histological analysis and representative images of the percentage of pho
hypoxic regions of LLC tumors from lethally irradiatedWTmice, transplanted with
from two independent experiments, total mice ten per genotype.
(G and H) qRT-PCR (G) and western blot (H) for REDD1 on BMDMs treated for 18
conditioned medium (TCM).
(I) Western blot in BMDMs treated for 18 hr with TCM in normoxia (TCM) or hypoxi
is unable to bind and inhibit the translation initiation factor eIF4E.
(J) Western blot in hypoxic WT and REDD1 KO TAMs-L, treated with or without
*p < 0.05 versus NRX (C and G), PIMOneg (D), or WT/WT (E and F); #p < 0.05 vers
and BM macrophages. The scale bars represent 50 mm. All graphs show mean ±REDD1 Deletion in TAMs Promotes Tumor Vessel
Normalization and Inhibits Metastasis
To understand the role of exacerbated REDD1 induction in hyp-
oxic TAMs, we deleted Redd1 in macrophages by transplanting
wild-type (WT) recipient mice with REDD1 knockout (KO) BM
cells (KO/WT). Upon reconstitution, KO/WT chimeras dis-
played normal blood counts, comparable with those of WT/
WT mice (Table S1). We then implanted LLC tumors subcutane-
ously. Consistent with the inhibitory role of REDD1 on mTORC1,
genetic deletion of Redd1 re-established the phosphorylation of
4E-BP1 and S6 (respectively a direct and indirect mTOR target)
in hypoxic TAMs (Figures 1E and 1F). In vitro, hypoxic, but not
normoxic, REDD1 KO TAMs-L displayed also increased phos-
phorylation of 4E-BP1 and S6 (Figure 1I), and this induction
was mTOR dependent (Figure 1J).
As an alternative to subcutaneous LLC tumors, we injected
E0771 breast cancer cells orthotopically or we reconstituted
4-week-old PyMT mice in a C57BL/6 background with WT and
REDD1 KO BM cells. In all three tumor models, Redd1 deletion
did not alter TAM accumulation nor their distribution in normoxic
versus hypoxic niches (Figures S2A–S2C). Although tumor
growth remained unchanged, the number of metastases in KO
versus WT chimeric mice was decreased (Figures 2A–2I).
Consistently, shedding of cancer cells from the primary tumor
to the circulation was significantly impaired in KO/WT versus
WT/WT LLC tumor-bearing mice (Figure 2J).
Hypoxic TAMs promote metastasis by influencing cancer cell
motility and invasion and by facilitating cancer cell extravasation,
survival, and growth at the metastatic site (Chen et al., 2011;
Qian et al., 2011). However, LLCmigration and collagen invasion
in vitro were equally promoted by hypoxic WT and REDD1 KO
TAMs (Figures S2D and S2E), and pulmonary lodging of cancer
cells systemically injected into the bloodstream did not differ
(Figure S2F). These data indicate that indirectmechanismsmight
be responsible for the reduced metastatic burden in tumor-
bearing KO/WT mice.
Hypoxic TAMs repress T cells and sustain aberrant and
dysfunctional tumor blood vessels (Henze and Mazzone,
2016). Although the numbers of tumor-infiltrating CD3+CD4+
T-BET+ TH1 cells, CD3
+CD4+GATA3+ TH2 cells, and CD3
+
CD8+ T cells were comparable in both chimeras (Figures
S2G–S2I), the tumor vascular trees were overtly different. Astivity
AMs) in LLC tumors.
LUT1 negative (GLUT1neg) or GLUT1 positive (GLUT1+) in normoxic (PIMOneg)
umor model.
UT1low/, NRX) and hypoxic (GLUT1high, HPX) regions of organs from healthy
to seven per condition.
area in normoxic PIMOneg or hypoxic PIMO+ regions in LLC tumors.
spho-4E-BP1-positive (E) and phospho-S6-positive (F) F4/80+ TAMs in PIMO+
WT or REDD1 KOBM cells (WT/WT and KO/WT, respectively). Pooled data
hr in normoxia (21% O2, NRX) or hypoxia (1% O2, HPX) with or without tumor-
a (HPX + TCM). The hyperphosphorylated g-form of 4E-BP1 is indicated, which
500 nM of the mTOR inhibitor Torin2.
us NRX lung and BMmacrophages (C) or BMDM (G); xp < 0.05 versus HPX lung
SEM. See also Figure S1.
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Figure 2. REDD1 Deletion in TAMs Inhibits Metastasis in Multiple Tumor Models
(A–F) Tumor growth (A, C, and E) and weight (B, D, and F) in the indicated tumor models.
(G–I) Lung metastatic nodules in LLC (G) (and representative H&E-stained lungs), E0771 (H), and PyMT (I) tumor-bearing mice. Data are pooled from three in-
dependent experiments, total mice 28 per genotype (LLC); from two independent experiments, total mice 18 per genotype (E0771); or from eight independent
experiments, total mice 15 per genotype (PyVT).
(J) Circulating LLC cells, quantified by Krt14 mRNA expression in the blood. Total mice 10 per genotype.
*p < 0.05 versus WT/WT. The scale bars represent 2 mm. All graphs show mean ± SEM. See also Figure S2 and Table S1.
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bolism (2016), http://dx.doi.org/10.1016/j.cmet.2016.09.008expected, LLC tumor blood vessels in WT/WT mice had a
disorganized, dilated appearance, with many protrusions. In
contrast, the tumor vasculature in KO/WT mice displayed a
smooth endothelial alignment and reduced vessel diameter
(Figure 3A). Similar features of vascular normalization were
found in the orthotopic E0771 breast cancer model as well as
in the PyMT-driven spontaneous breast cancer model (Figures
3B and 3C). Tumor vessels of KO/WT mice were more
covered with pericytes (Figures 3D–3F) and hadmore abundant
vascular endothelial (VE)-cadherin junctions (Figure 3G), which
together provide stability and tightness to the blood vessel bar-
rier (Mazzone et al., 2009; Xian et al., 2006). Functionally, this re-
sulted in improved perfusion, lower vascular permeability, and
reduced tumor hypoxia (Figures 3H–3N) despite comparable
vessel density (Figures S2J–S2L). These morphological and
functional tumor vascular changes have been already shown
to reduce metastasis (Maes et al., 2014; Mazzone et al., 2009;
Rolny et al., 2011).
To reinforce the evidence that REDD1-deficient TAMs were
the main contributors to the observed phenotype, we depleted
macrophages in WT/WT and KO/WT mice by intraperitoneal
(i.p.) administration of an anti-CSF-1R blocking antibody (clone4 Cell Metabolism 24, 1–15, November 8, 2016AFS98), which resulted in about 90% reduction in TAM density
in both genotypes (Figure 4A). As expected (Rolny et al., 2011),
TAM depletion reduced both tumor growth and metastasis in a
WT context, but this treatment did not further reduce metastatic
growth in REDD1 KO chimeras compared with mice treated with
an IgG control (Figures 4B and 4C). Following anti-CSF-1R treat-
ment, the tumor vasculature in WT chimeric mice resembled the
same features observed in REDD1KO/WTmice, whereas TAM
depletion in the latter mice did not further impinge on tumor ves-
sels (Figures 4D–4G), altogether arguing that the effect of he-
matopoietic REDD1 deletion on metastasis and blood vessels
reflects mostly a change in TAMs and not in other hematopoietic
cells.
Metastases were also prevented when LLC tumors were
grown in non-transplanted REDD1 KO mice (in which all stromal
cells including the endothelium itself are deficient for Redd1)
(Figure 4H), with increased vessel functionality (Figures 4I and
4J). These data exclude the possibility that all the aforemen-
tioned data are related to a specific condition triggered by
whole-body irradiation prior to transplantation (Ahn and Brown,
2008) and further support the prominent role of REDD1 in in-
flammatory cells, rather than in other stromal components. In
Please cite this article in press as: Wenes et al., Macrophage Metabolism Controls Tumor Blood Vessel Morphogenesis and Metastasis, Cell Meta-
bolism (2016), http://dx.doi.org/10.1016/j.cmet.2016.09.008conclusion, deficiency of REDD1 in TAMs promotes vessel nor-
malization and reduces metastasis in several tumor types.
REDD1 Deletion in Hypoxic TAMs Reinforces Glycolysis
By performing metabolic assays, we observed that hypoxic
TAMs showed an increase in glycolysis (Figure 5A). However,
upon Redd1 deletion, the glycolytic flux was further increased
in an mTOR-dependent manner (Figure 5A).
In turn, fatty acid oxidation (FAO) was decreased in hypoxic
REDD1 KO TAMs, while glucose and glutamine oxidation re-
mained unchanged (Figures 5B–5D). When this was translated
in terms of ATP production, we observed an equal balance in
glycolytic versus mitochondrial contribution to the ATP pool in
hypoxic WT TAMs (Figure 5E). Differently, in hypoxic REDD1
KO TAMs, glycolysis was the main contributor to the ATP pool,
a characteristic of in vitro polarized M1 macrophages (Rodrı´-
guez-Prados et al., 2010), whereas the percentage of ATP mole-
cules from fatty acid oxidation, a characteristic of M2 macro-
phages, was reduced so that the total ATP levels and energy
charge remained unchanged (Figures 5F and 5G). Although
also reduced in hypoxic versus normoxic WT cells, ATP-linked
mitochondrial oxygen consumption reached the lowest levels
in hypoxic (GLUT1high) REDD1 KO TAMs, and this difference
was mTOR dependent (Figure 5H). In vitro analysis showed
that only the combined induction of REDD1 by hypoxia and tu-
mor-derived stimuli in the TCM (but not each in condition alone)
was able to effectively brake glycolytic metabolism (Figures 5I
and 5J).
When looking at normoxic TAMs, Redd1 deficiency did not
alter either glycolysis or the contribution of the four major fluxes
(glycolysis, glucose oxidation, glutamine oxidation, and FAO) to
the ATP pool (Figures 5A and 5K) opening the question if REDD1
in the more oxidative (GLUT1low/) TAM fraction might play a role
in the control of mitochondrial ROS formation (Horak et al.,
2010).
In line with the observed increase in glycolysis, hypoxic
REDD1 KO TAMs (but not the normoxic ones) showed the high-
est levels of GLUT1, which was accompanied by a strong in-
crease in glucose uptake (Figures 5L–5N). Similarly, GLUT1
expression and glucose uptake was enhanced in hypoxic
REDD1 KO TAMs-L when compared with hypoxic WT TAMs-L
(Figures 5O and 5P). Both in TAMs and in TAMs-L, this induction
was dependent on mTOR (Figures 5N and 5O).
Altogether, REDD1 deletion in hypoxic TAMs reinforces their
glycolytic phenotype at the expense of oxidative pathways,
and in particular of FAO, via mTOR activation.
Increased Glycolysis in REDD1 KO TAMs Causes Tumor
Vessel Normalization by Competing for Glucose with
Endothelial Cells
In the attempt to understand how the metabolic changes
observed in hypoxic (GLUT1high) TAMs could influence their
phenotype, we performed RNA sequencing on WT and
REDD1 KO CD11b+ F4/80+ GLUT1high macrophages sorted us-
ing fluorescence-activated cell sorting (FACS) from LLC tumors
(ArrayExpress: E-MTAB-5032). In general, only five genes
were differentially expressed (Benjamini-Hochberg adjusted
p < 0.05) (Table S2). Heatmap analysis of M1 and M2 gene
expression (Mantovani et al., 2002; Mosser and Edwards,2008; Sica and Mantovani, 2012) did not reveal distinct signa-
tures in WT versus REDD1 KO GLUT1high TAMs or in WT versus
REDD1 KO GLUT1low/ TAMs (Figures S3A and S3B). Accord-
ingly, histological analysis and FACS quantifications could
not uncover an imbalance in TAM subsets (Figures S3C–S3F).
In a similar fashion, while self-contained gene set enrichment
analysis showed that a predefined angiogenic gene sig-
nature (Mazzieri et al., 2011; Murdoch et al., 2008) was signifi-
cantly upregulated in GLUT1high TAMs as compared with
Glut1low/ TAMs (p = 0.0001), GLUT1high and Glut1low/ KO
TAMs did not differ from their WT counterparts (Figure S3G).
We then hypothesized that enhanced glucose uptake and con-
sumption by REDD1KOGLUT1high TAMs could install a compe-
tition with tumor endothelial cells (tECs) for their more important
fuel (De Bock et al., 2013). Of relevance, in a tumor, per each
endothelial cell (EC), there are about 20 TAMs, so that the
weight of metabolic differences in TAMs is suddenly increased
by the large representation of these cells (our data in LLC
tumors, Figure S4A; Shigeoka et al., 2013; Takeuchi et al.,
2016). Interestingly, in WT/WT mice, glucose uptake by
tECs was twice the uptake measured in TAMs (Figure 6A). In
contrast, in KO/WTmice, TAMs and tECs had similar glucose
uptake, reflecting stronger glucose uptake by REDD1 KO
versus WT TAMs, which goes at the expense of endothelial
glucose consumption, as proved by the fact that TAM depletion
abolished this trend (Figure 6A).
Previous data have shown that glycolysis blockade renders
ECs more quiescent, and this is due mostly to the influence of
cytosolic ATP on cytoskeleton rearrangements that in turn are
associated with the redistribution of cell-cell contacts (De Bock
et al., 2013). Because the in vivo data showed an alteration in
endothelial junctions without a difference in vessel numbers
(nor in EC survival or apoptosis; Figures S4B and S4C), we
focused our attention on this parameter by using in vitro assays.
We first seededWT and REDD1 KO TAMs-L in the lower part of a
Boyden chamber and placed a confluent layer of human umbil-
ical vein ECs (HUVECs) on the upper side of a 0.4-mm-pore filter
(that allows molecule exchange but impedes cell migration). In
the presence of WT TAMs-L, VE-cadherin junctions displayed
a rope ladder-like pattern (which is typical of an activated endo-
thelium; Bentley et al., 2014), while in presence of REDD1 KO
TAMs-L, VE-cadherin was linearly distributed along the cell-
cell junction, which is a sign of stability (Figures 6B and 6C). In
the presence of higher glucose (5.5 mM instead of 0.6 mM,
roughly corresponding to the concentrations of glucose in circu-
lation and in the tumor; Ho et al., 2015), VE-cadherin junctions
were activated independently of the presence of WT or REDD1
KO TAMs-L (Figures 6B and 6C). Functionally, only in low
glucose, the presence of REDD1 KO TAMs-L was associated
with increased transendothelial electrical resistance (TEER),
which is in linewith the tighter endothelial barrier observed in vivo
(Figure 6D).
To verify if the increase in glycolysis or glucose uptake in
REDD1 KO TAMs was the underlying cause of the observed
phenotype, we sought to delete in macrophages only, both
Redd1 and Pfkfb3, a key glycolytic activator responsible for
enhanced glycolysis and reduced oxygen consumption in
REDD1 KO TAMs (Figures S4D and S4E). Therefore, we inter-
crossed REDD1 KO mice with Pfkfb3lox/loxxCsf1r.Mer2.CreCell Metabolism 24, 1–15, November 8, 2016 5
(legend on next page)
6 Cell Metabolism 24, 1–15, November 8, 2016
Please cite this article in press as: Wenes et al., Macrophage Metabolism Controls Tumor Blood Vessel Morphogenesis and Metastasis, Cell Meta-
bolism (2016), http://dx.doi.org/10.1016/j.cmet.2016.09.008
Figure 4. Macrophage Depletion Abrogates the Vascular and Metastatic Differences Induced by REDD1 Deletion in TAMs
(A) F4/80+ macrophage accumulation in LLC tumors of mice treated with control IgG isotype or TAM-depleting anti-CSF-1R monoclonal antibodies.
(B and C) LLC tumor growth (B) and metastatic index (C).
(D) Representative confocal images of CD31+ blood vessel morphology.
(E–G) Pericyte coverage (E), blood vessel perfusion (F), and tumor hypoxia (G). Total mice 8–10 per condition.
(H) Metastatic nodules in lungs of non-transplanted LLC tumor-bearing mice.
(I and J) Blood vessel perfusion (I) and tumor hypoxia (J) in non-transplanted LLC tumor-bearing mice. Total mice 7 per genotype.
*p < 0.05 versus WT/WT or WT; #p < 0.05 versus IgG. The scale bars represent 50 mm. All graphs show mean ± SEM.
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bolism (2016), http://dx.doi.org/10.1016/j.cmet.2016.09.008mice, the latter enabling tamoxifen-inducible, macrophage-spe-
cific deletion of Pfkfb3 (Figure S4F; Chesney et al., 2005; Qian
et al., 2011). In subcutaneously grown LLC tumors, PFKFB3dele-
tion in REDD1 KO TAMs (REDD1bmDPFKmoD) resulted in an
abnormal vasculature, similar to that found in tumors in which
TAMs were WT for both genes (Figure 6E). Indeed, tumor bloodFigure 3. REDD1 Deletion in TAMs Promotes Tumor Blood Vessel Nor
(A–C) CD31+ blood vessel morphology in the indicated tumor models, quantificatio
from confocal Z-stacks acquired on 80-mm-thick sections.
(D and E) Percentage of aSMA+ pericyte-covered vessels over the total number o
images) and E0771 tumors (E).
(F) Percentage of NG2+ pericyte-covered vessels in PyMT tumors.
(G) Ratio of VE-cadherin (VEC) to CD31 staining and representative confocal ima
(H–J) Percentage of lectin-FITC+ perfused vessels in LLC (H, and representative
(K) Quantification and representative images of the percentage of 70 kDa dextra
(L–N) Percentage of pimonidazole-positive hypoxic area acquired in LLC (L, and r
three independent experiments, total mice 28 per genotype (LLC); from two ind
dependent experiments, total mice 15 per genotype (PyVT).
*p < 0.05 versus WT/WT. The scale bars represent 10 (G) or 50 mm (A–D, H, K,vessels in REDD1bmDPFKmoD mice were sparsely covered with
pericytes and poorly perfused, leading to persistent hypoxia
(Figures 6F–6K). Of note, PFKFB3 deletion altered neither
TAM infiltration nor vessel density (Figures S4G and S4H).
Concomitant with the abnormal tumor vasculature and increased
hypoxia, PFKFB3 deletion abrogated the protective effect ofmalization
n of vessel diameter, and representative maximum intensity projection images
f CD34+ vessels acquired on thin sections of LLC tumors (D, and representative
ges of thick LLC tumor sections.
images), E0771 (I), and PyMT tumors (J).
n+ leaky vessels in LLC tumors.
epresentative images), E0771 (M), and PyMT tumors (N). Data are pooled from
ependent experiments, total mice 18 per genotype (E0771); or from eight in-
and L). All graphs show mean ± SEM. See also Figure S2.
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Figure 5. REDD1 Expression in Hypoxic TAMs Limits Their Glycolytic Metabolism
(A) Glycolytic flux in GLUT1low/ (NRX) and GLUT1high (HPX) CD11b+ F4/80+ TAMs, sorted using FACS from LLC tumors treated with Torin2 or vehicle.
(B) Fatty acid oxidation in TAMs treated or not ex vivo with 100 nM Torin2.
(C and D) Glucose (C) and glutamine (D) oxidation in GLUT1high CD11b+ F4/80+ TAMs.
(E) Flux analysis showing the contribution of fatty acid oxidation (FAO), glucose oxidation (GO), glycolysis (Glyc), and glutamine oxidation (QO) in percentage of
the total cellular ATP pool in hypoxic GLUT1high CD11b+ F4/80+ TAMs.
(F and G) LC-MS measurement of total cellular ATP content (F) and energy charge ([ATP] + 1/2[ADP]/[ATP] + [ADP] + [AMP]) (G) in F4/80+ TAMs.
(A–G) Pooled data from two independent experiments, total mice six per genotype in technical triplicates.
(H) Oxygen consumption rate (OCR) in TAMs, treated or not ex vivo with Torin2. Total mice three per genotype in technical triplicates.
(I and J) Glycolysis and OCR in REDD1 WT and KO BMDMs treated for 18 hr in normoxia (21% O2, NRX) or hypoxia (1% O2, HPX) with or without TCM.
Representative graphs from two independent experiments, total mice six per genotype in technical triplicates.
(K) Flux analysis in normoxic GLUT1low/ CD11b+ F4/80+ TAMs. Total mice six per genotype in technical triplicates.
(L) FACS analysis of GLUT1 mean signal intensity in GLUT1low/ and GLUT1high F4/80+ TAMs.
(M) Glucose uptake in TAMs measured by FACS quantification of the signal intensity of a fluorescently labeled glucose analog (2NBDG) in GLUT1low/ and
GLUT1high F4/80+ macrophages, injected intratumorally. Total mice six per genotype.
(N) 14C-2-deoxyglucose uptake in TAMs, treated or not ex vivo with Torin2. Total mice three per genotype in technical triplicates.
(O) Western blot for GLUT1 in hypoxic TAMs-L treated with or without Torin2. Representative of two independent experiments.
(P) 14C-2-deoxyglucose uptake in hypoxic TAMs-L. Pooled data from three independent experiments, total mice six per genotype in technical triplicates.
*p < 0.05 versus WT/WT or WT; #p < 0.05 versus NRX or GLUT1low/; xp < 0.05 versus HPX + vehicle or HPX untreated. All graphs show mean ± SEM.
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tumor growth, remained unaffected (Figures 6L–6N). Reduc-
tion of glucose consumption by REDD1bmDPFKmoD TAMs
increased endothelial glucose uptake to the same levels as in
REDD1wtPFKwtmice (Figure 6O). In conclusion, increased glycol-
ysis upondeletion of REDD1 in hypoxic TAMsbrings these cells in
competition for glucose with the tumor endothelium. As a result,
lower glucose availability in the perivascular space thwarts endo-
thelial hyperactivation, which leads to vascular stabilization and
metastasis inhibition (Figure 6P).
Opposite Role of mTOR Pathway in Cancer Cells
and TAMs
Pharmacologic inhibition of mTOR has been proposed in the
clinic because of the relevance of this pathway in boosting pro-
tein synthesis and cancer cell proliferation (Don and Zheng,
2011; Hsieh et al., 2012). According to the aforementioned
data, however, mTOR activation would unleash tumor-inhibit-
ing functions in TAMs. To validate this hypothesis, we adminis-
tered Torin2 to WT/WT and KO/WT tumor-bearing mice.
Although tumor growth inhibition by Torin2 was comparable in
both chimeras, metastatic index was boosted up to the same
levels so that REDD1 deficiency in TAMs was no longer benefi-
cial (Figures 7A and 7B). This phenotype was associated by
increased tumor vessel abnormalization and hypoxia in
Torin2-treated WT/WT and KO/WT mice, which were now
comparable (Figures 7C–7F). To dissect the effect of mTOR in-
hibition in cancer cells and in the tumor stroma, we compared
the outcome of mTOR silencing in LLC cells (Figure S5A) versus
systemic administration of Torin2. Torin2 decreased the volume
of LLC tumors by 30% andmTOR knockdown in cancer cells by
70% (Figure 7G). However, the effect of combined mTOR
silencing and systemic Torin2 administration was not additive
but conversely re-established tumor growth almost at the
same level as observed with Torin2 alone (Figure 7G). As ex-
pected, mTOR silencing in cancer cells reduced metastases,
whereas systemic Torin2 treatment drastically increased me-
tastases, thereby blunting the beneficial effects of mTOR
silencing in LLC cells (Figure 7H). Accordingly, normalized
blood vessels and reduced hypoxia upon mTOR silencing in
LLC cells was abrogated by systemic Torin2 treatment (Figures
7I–7L). Of note, blood vessel density was equally reduced in all
treatment groups (Figure S5B), most likely because of reduced
VEGF production after mTOR inhibition in the cancer cells, as
already described (Guba et al., 2002). To restrict the effect of
mTOR inhibition to the TAMs (and not to other stromal cells),
we proposed Torin2 administration in combination with the
TAM-depleting antibody anti-CSF-1R. In this setting, while
Torin2 and anti-CSF-1R together additively inhibited tumor
growth (Figure 7M), the metastatic boost observed with sys-
temic Torin2 alone was greatly prevented when combined
with TAM depletion (Figure 7N). Accordingly, the increase in
vessel abnormalization and tumor hypoxia upon Torin2 treat-
ment was partially reversed as well (Figures 7O–7R). Thus, the
anti-tumor effect of systemic mTOR inhibition occurs mainly
through the inhibition of this pathway in cancer cells, while it
is partly countered by the effect on TAMs in which, contrary
to REDD1 knockout and mTOR activation, mTOR blockade
further sustains tumor vessel abnormalization and metastasis.DISCUSSION
So far, the intertwined relationship between metabolism and
macrophages in the context of cancer is completely unexplored.
Starting from our previous observations that hypoxic TAMs ac-
quire pro-angiogenic and immune suppressive features (Ca-
sazza et al., 2013), we now show that REDD1, a negative regu-
lator of mTORC1 (Brugarolas et al., 2004), reaches the highest
level of induction in response to tumor hypoxia, and we suggest
that this induction plays a key role in themetabolic switch of hyp-
oxic TAMs and in turn on tumor oxygenation and vascularization.
When preventing TAMs’ entry into the hypoxic regions of the
tumor, the contributions of these cells to cancer cell spreading,
angiogenesis, and immunosuppression are all affected (Casazza
et al., 2013; Laoui et al., 2014). The present data suggest that
metabolic changes dictated by REDD1-mediated mTOR inhibi-
tion in TAMs specifically affect vascular remodeling and oxygen
delivery without modulating the influence of TAMs on cancer cell
invasion or on the immune system. In support of this idea, spe-
cific knockout of PFKFB3 in macrophages, restoring the glyco-
lytic flow of REDD1 KO TAMs toWT levels, prevents tumor blood
vessel normalization without altering vessel density or tumor
growth. The effect of this metabolic rewiring on vessel morpho-
genesis is due mostly to enhanced glucose uptake and glycol-
ysis by the hypoxic TAMs that install a competition with tECs,
which in response to lower glucose rewire their phenotype
toward quiescence and engage stable cell-cell junctions. It re-
mains to be addressed if other tumor cells besides the endothe-
lium (e.g., pericytes or cancer cells) enter into competition with
TAMs for their fuel. Likely, glucose competition occurs also in
a WT context in which, however, the surge of TAM-derived
angiogenic cues prevails, as suggested by the fact that TAM
depletion normalizes the tumor vasculature. By genetic means,
the capacity of TAMs to compete for glucose with tECs is
enhanced to a level that it counters the overall angiogenic burst
of the tumor environment.
A possible question that derives from our work is how hypoxic
TAMs can have access to the glucose coming from the blood.
Likely, the glucose in circulation (which normally diffuses for
longer distances than oxygen; Gatenby and Gillies, 2004) can
reach the hypoxic TAMs because neoplastic cells at the vascular
rim oxidize lactate (instead of glucose) in favor of hypoxic and
glycolytic cancer cells (Allen et al., 2016).
Previous literature has shown that mTOR hyperactivation after
genetic deletion of its negative regulator TSC1 hinders M2-like
responses to IL-4 or other M2 stimuli (Byles et al., 2013; Zhu
et al., 2014), whereas pharmacologic mTOR inhibition promotes
an anti-inflammatory M2 phenotypic shift (Han et al., 2016). The
present study moves the field forward and sheds light into the
metabolic control by the REDD1-mTOR pathway in TAMs. In
line with our previous findings that hypoxia per se does not
change the ratio between different TAM subsets (Laoui et al.,
2014), a metabolic change in hypoxic TAMs only fine-tunes
the angiogenic properties of TAMs without altering the accumu-
lation of distinct M1- or M2-like subpopulations and without
altering the actual balance between pro-angiogenic (M2) versus
anti-angiogenic (M1) cytokines. Instead, mTOR activation by
REDD1 deletion enhances the expression of the main glucose
transporter GLUT1 and reinforces glucose uptake. A previousCell Metabolism 24, 1–15, November 8, 2016 9
Figure 6. Increased Glycolysis in REDD1 KO TAMs Causes Tumor Vessel Normalization by Competing for Glucose with ECs
(A) In vivo 2NBDG glucose uptake in F4/80+ macrophages and CD31+ ECs, in mice treated with control IgG isotype or TAM-depleting anti-CSF-1R monoclonal
antibodies. Total mice six per condition.
(legend continued on next page)
10 Cell Metabolism 24, 1–15, November 8, 2016
Please cite this article in press as: Wenes et al., Macrophage Metabolism Controls Tumor Blood Vessel Morphogenesis and Metastasis, Cell Meta-
bolism (2016), http://dx.doi.org/10.1016/j.cmet.2016.09.008
Please cite this article in press as: Wenes et al., Macrophage Metabolism Controls Tumor Blood Vessel Morphogenesis and Metastasis, Cell Meta-
bolism (2016), http://dx.doi.org/10.1016/j.cmet.2016.09.008study has already shown that GLUT1 overexpression in macro-
phages is sufficient to enhance glycolysis (Freemerman et al.,
2014). On this basis, and given the evidence that mTORC1-
mediated phosphorylation of 4E-BP1 results in its inhibition
and consequently in the block of Glut1 mRNA translation (Taha
et al., 1999), we suppose that the observed effects on GLUT1
protein levels and glucose uptake in REDD1 KO TAMs (and
TAMs-L) are mediated, at least in part, by 4E-BP1.
During physiological processes such as embryogenesis
and organ formation, macrophages are known to display
an important pro-angiogenic function (Fantin et al., 2010;
Stefater et al., 2011). Our results suggest that hypoxic upre-
gulation of REDD1 in normal situations is dispensable as
REDD1 KO mice are normal and do not show overt patholog-
ical signs. However, under stress conditions and in combina-
tion with tumor-derived stimuli, REDD1 is induced beyond
proportions. As a consequence, deletion of REDD1 in the
hypoxic TAMs remarkably upregulates glucose competition
so that the blood vessels become smoothly aligned, tightly
connected, and well-covered by pericytes. Tumor oxygena-
tion and vessel coverage together prevent metastasis forma-
tion (Figure 6P).
Because hyperactivation of mTOR signaling is found in many
cancers and given that alterations in the mTOR pathway are
associated with cancer development and progression (Hsieh
et al., 2012; Sun et al., 2015), mTOR inhibitors provide thera-
peutic value in a number of cancers, in both preclinical and clin-
ical settings (Don and Zheng, 2011; Li et al., 2014). Interestingly,
in PTEN-deficient glioblastomas, the mTOR inhibitor rapamycin
reduces cancer cell proliferation and improves clinical out-
comes in 50% of the patients (Cloughesy et al., 2008). In those
patients who do not respond, cancer cells remain in any case
sensitive to rapamycin in vitro, suggesting that resistance is
likely due to cancer cell-extrinsic mechanisms. Following these
observations and on the basis of the present findings, a
possible future study could aim to look at REDD1+ TAMs in cor-
relation with treatment failures of rapalogs and other mTOR-tar-
geting drugs.
Altogether, our results establish a causative link between TAM
metabolism in hypoxia and tumor vessel morphogenesis.(B and C) Percentage of continuous (quiescent) or discontinuous (remodeling
chamber with hypoxic TAMs-L in the lower compartment in either 0.6 or 5.5 mM
monolayer (C).
(D) Transendothelial electrical resistance of a HUVECmonolayer co-cultured with
independent experiments, total mice six per genotype in technical triplicates.
(E) Representative confocal images of CD31+ blood vessel morphology in tumors
in macrophages only (REDD1bmDPFKmoD) or with the relative control BM cells.
(F and G) aSMA+ pericyte coverage.
(H and I) Lectin-FITC+ perfusion.
(J and K) Pimonidazole-positive hypoxic tumor area.
(L and M) LLC tumor growth (L) and weight at the time of dissection (M).
(N) Quantification of the number of lung metastases.
(O) In vivo 2NBDG glucose uptake in TAMs and tECs. Total mice six per conditio
(P) Schematic overview of the data showing that deletion of REDD1 triggers mT
Highly glycolytic REDD1 KO TAMs enter in competition with tumor ECs for glucose
hypoxia and metastasis. In WT TAMs, massive REDD1 induction by hypoxia an
glucose competition is not installed, while their release of angiogenic factors prom
cell intravasation and metastasis.
All experiments, total mice ten per genotype. *p < 0.05 versus WT or REDD1wt; #
50 mm (E), and 100 mm (G, I, and K). All graphs show mean ± SEM. See also FiguEXPERIMENTAL PROCEDURES
More detailed methods can be found in the Supplemental Experimental
Procedures.
Animals
REDD1KOmicewere generated by Lexicon exclusively for Quark Pharmaceu-
ticals and are the property of Quark Pharmaceuticals. Pfkfb3lox/lox were
provided by J. Chesney (University of Louisville). Csf1r.Mer2.Cre mice were
obtained from J. Pollard (University of Edinburgh). C57BL/6 and FVB MMTV-
PyMT mice were purchased from Harlan and Charles River, respectively.
FVB MMTV-PyMT mice were then backcrossed in a C57BL/6 background in
our facility. Acute deletion of PFKFB3 was obtained by i.p. injection of tamox-
ifen (1 mg/mouse/day) for 5 days before subcutaneous implantation of LLC
cancer cells. All mice used were on a C57BL/6 background and between
5 and 15 weeks old, without specific gender selection. In all experiments,
littermate controls were used.
Bone Marrow Transplantation
Five- to 6-week-old C56BL/6 or 3- to 4-week-old PyMT recipient mice were
irradiated with 9.5 Gy. Subsequently, 107 bone marrow cells from the appro-
priate genotype were injected intravenously via the tail vein. Tumor experi-
ments were initiated 5 weeks after bone marrow reconstitution.
Tumor Models
Housing and all experimental animal procedures were approved by the
Institutional Animal Care and Research Advisory Committee of the KU
Leuven. LLC cells (1 3 106) were injected subcutaneously or 5 3 105
E0771 cells were injected orthotopically in the mammary fat pad. Circu-
lating cancer cells were detected by qRT-PCR on blood for cytokeratin
14 (Krt14, not present in blood from healthy mice). Lung metastatic nodules
were contrasted after intratracheal injection of 15% India ink solution.
Macrophage depletion was achieved by daily i.p. injection of 20 mg/kg
mouse anti-CSF-1R antibodies (clone AFS98; BioXcell) or isotype IgG con-
trol (Sigma-Aldrich). Mice were pretreated for 3 days with anti-CSF-1R
before LLC tumor cell injection. Acute deletion of PFKFB3 was obtained
by i.p. injection of tamoxifen (1 mg/mouse/day) for 5 days before subcu-
taneous implantation of LLC cancer cells. Torin2 was given by daily gavage
at 20 mg/kg.
Hypoxia Assessment
Tumor hypoxia was detected 1 hr after i.p. injection of 60 mg/kg pimonidazole
hydrochloride into tumor-bearing mice. Mice were sacrificed and tumors har-
vested. To detect the formation of pimonidazole adducts, tumor cryosections
were immunostained with Hypoxyprobe-1-Mab1 (Hypoxyprobe kit; Chemi-
con) following the manufacturer’s instructions.) VE-cadherin junctions in HUVECs co-cultured on a 0.4-mm-pore Boyden
glucose (B) and representative images of VE-cadherin staining in the HUVEC
hypoxic TAMs-L in either 0.6 or 5.5 mM glucose. Representative graphs of two
of WTmice transplanted with REDD1-deficient BM conditionally lacking Pfkfb3
n.
OR activity in hypoxic TAMs, which enhances glucose uptake and glycolysis.
, which leads to endothelial quiescence and vessel maturation, which prevents
d other tumor-related stimuli brakes their glycolytic metabolism. As a result,
otes the formation of abnormal and leaky blood vessels, overall favoring cancer
p < 0.05 versus 0.6 mM glucose or PFKwt. The scale bars represent 10 mm (C),
res S3 and S4 and Table S2.
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Figure 7. Opposing Activity of mTOR in Cancer Cells and TAMs
(A and B) LLC tumor growth (A) and metastatic index (B) in BM-transplanted mice treated with vehicle or Torin2.
(C–F) Representative images of CD31-stained thick sections (C), pericyte coverage (D), blood vessel perfusion (E), and hypoxia (F) in LLC tumors from mice
treated with vehicle or Torin2. Total mice eight per condition.
(legend continued on next page)
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Perfused tumor vessels were counted on tumor sections from mice injected
intravenously with 0.05mg fluorescein isothiocyanate (FITC)-conjugated lectin
(Lycopersicon esculentum; Vector Laboratories). Leaky blood vessels were
histologically assessed upon intravenous injection of 70 kDa biotin-conjugated
dextran (Molecular Probes). After 10 min, mice were perfused by intracardiac
injection of saline for 5 min, and tumors were collection in 2% paraformalde-
hyde (PFA).
FACS of Tissue- and Tumor-Associated Macrophages
Tumor-bearing mice were sacrificed by cervical dislocation and tumors were
harvested. Tumors or other organs were minced in RPMI medium containing
0.1% collagenase type I and 0.2% dispase type I and incubated in the same
solution for 30 min at 37C. The myeloid cell population in the tumor single
cell suspension was enriched by magnetic isolation, using CD11b-conjugated
magnetic beads, and subsequently stained for GLUT1 and the pan-macro-
phage marker F4/80.
Metabolic Assays
Glycolysis and oxidation of other substrates were determined on sorted
GLUT1low/ and GLUT1high CD11b+ F4/80+ TAMs directly or, when indicated,
after overnight incubation with or without 100 nM Torin2 in normoxia or hypox-
ia, respectively, using radioactively labeled tracers. Oxygen consumption rate
(OCR) was measured using the Seahorse XF24 analyzer. To characterize
glucose uptake in vivo, LLC tumor-bearing mice were injected intratumorally
with 2-NBDG, and F4/80+ TAMs and CD31+ ECs were analyzed using FACS.
Macrophage-EC Co-culture In Vitro
BMDMs (53 105) were seeded in a 24-well plate and differentiated to hypoxic
TAMs-L (see above). The cells were then washed and incubated in M199 me-
dium containing 5% fetal bovine serum and 0.6 or 5.5 mM glucose together
with 53 104 HUVECs seeded 2 days before on a 0.4-mm-pore Boyden cham-
ber insert (Corning). For VE-cadherin analysis, inserts containing the HUVEC
monolayer were fixed after 8 hr of co-culture with 4%PFA for 7min and stained
with goat anti-VE-cadherin (R&D Systems). Transendothelial electrical resis-
tance was measured with the EVOM2 Epithelial Voltohmeter (World Precision
Instruments) after 24 hr of co-culture.
Statistical Analysis
Data entry and all analyses were performed in a blinded fashion. All statistical
analyses were performed using GraphPad Prism software. Statistical signifi-
cance was calculated using two-tailed unpaired t tests on two experimental
conditions or two-way ANOVA when repeated measures were compared,
with p < 0.05 considered statistically significant. All graphs show mean
values ± SEM.
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The accession number for the RNA sequencing data reported in this paper is
ArrayExpress: E-MTAB-5032.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
five figures, and two tables and can be found with this article online at http://
dx.doi.org/10.1016/j.cmet.2016.09.008.(G and H) Tumor growth (G) and metastatic index (H) in mice injected with LLC c
treated with vehicle or Torin2. shRNA, short hairpin RNA.
(I–L) Representative images of CD31-stained thick sections (I), pericyte coverage
condition.
(M and N) LLC tumor growth (M) and metastatic index (N) in mice treated with ve
(O–R) Representative images of CD31-stained thick sections (O), pericyte cov
condition.
*p < 0.05 versusWT/WT (A–F), vehicle (G–L), or vehicle and IgG (M–R); #p < 0.05
scale bars represent 50 mm. All graphs show mean ± SEM.AUTHOR CONTRIBUTIONS
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